Groundbreaking Study, New AHA Guidelines
DEFUSE 3 was an NIH-funded study that enrolled stroke patients with favorable Rapid profiles and randomized them to treatment with endovascular thrombectomy vs. standard medical therapy between 6 and 16 hours after stroke onset. The study demonstrated dramatic improvements in stroke outcomes. The main results of the study are shown above. Rapid-selected patients randomized to endovascular thrombectomy had substantially better outcomes on the modified Rankin scale (mRS) 90 days after the stroke. The mRS scores range from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, and 6 death. The percentage of patients who were functionally independent, defined as a score on the modified Rankin scale of 0 to 2, at 90 days was 45% in the endovascular-therapy group, as compared with 17% in the medical-therapy group.
In addition to nearly 3 times as many patients having a favorable outcome from their stroke, the rate of severe disability and death was reduced from 42% to 22%. This represents the largest reduction in unfavorable outcomes ever achieved. Learn More.